HealthLinx Limited (ASX:HTX), has reached an agreement with The University of Liverpool (UK) to in-license additional patented biomarker technology and antibodies that has shown efficacy in detecting grade I & II ovarian cancer.HealthLinx and The University of Liverpool (UK) have been jointly developing this technology over the past twelve months which has potential to be the world’s first commercially available, multi-marker early stage ovarian cancer diagnostic. Preliminary studies indicate detection of early stage ovarian cancer (grade I & II) and discrimination between the two major types of ovarian cancer (mucinous and serous tumors). No product with either of these benefits is available in the world today.
